Quadrature Capital Ltd Purchases Shares of 11,754 IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Quadrature Capital Ltd acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 11,754 shares of the company’s stock, valued at approximately $6,346,000.

Several other institutional investors also recently modified their holdings of IDXX. Norges Bank acquired a new position in shares of IDEXX Laboratories during the 4th quarter worth about $512,190,000. International Assets Investment Management LLC increased its stake in shares of IDEXX Laboratories by 51,631.3% during the 4th quarter. International Assets Investment Management LLC now owns 547,834 shares of the company’s stock worth $304,075,000 after purchasing an additional 546,775 shares during the last quarter. Capital Research Global Investors acquired a new position in shares of IDEXX Laboratories during the 4th quarter worth about $135,910,000. TD Asset Management Inc increased its stake in shares of IDEXX Laboratories by 178.8% during the 4th quarter. TD Asset Management Inc now owns 260,008 shares of the company’s stock worth $144,317,000 after purchasing an additional 166,751 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in shares of IDEXX Laboratories during the 4th quarter worth about $78,001,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently commented on IDXX. Barclays reduced their target price on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a report on Thursday, May 2nd. BTIG Research began coverage on shares of IDEXX Laboratories in a report on Thursday. They set a “buy” rating and a $580.00 target price for the company. Stifel Nicolaus reduced their target price on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a report on Monday, June 24th. StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. Finally, William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $585.89.

IDEXX Laboratories Stock Performance

NASDAQ IDXX traded down $0.97 during trading on Friday, reaching $469.71. The company’s stock had a trading volume of 588,415 shares, compared to its average volume of 478,889. The company has a current ratio of 1.57, a quick ratio of 1.16 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $38.79 billion, a price-to-earnings ratio of 45.47, a price-to-earnings-growth ratio of 3.85 and a beta of 1.32. IDEXX Laboratories, Inc. has a 12 month low of $372.50 and a 12 month high of $583.39. The firm has a 50 day moving average price of $493.61 and a 200 day moving average price of $517.16.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Wednesday, May 1st. The company reported $2.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.13. The firm had revenue of $964.10 million during the quarter, compared to the consensus estimate of $965.43 million. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. As a group, equities analysts anticipate that IDEXX Laboratories, Inc. will post 11 EPS for the current fiscal year.

Insider Activity

In other news, Director Bruce L. Claflin sold 200 shares of the business’s stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $540.80, for a total value of $108,160.00. Following the completion of the transaction, the director now directly owns 161 shares in the company, valued at approximately $87,068.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.